Stock Groups

Sweden extends pause of Moderna vaccine for younger age group -Breaking

© Reuters.

STOCKHOLM (Reuters – Sweden extends the pause Moderna The COVID-19 vaccine is available to people 30 years and older. It’s a preventative against rare side effects that can lead to death.

According to the Health Agency, October was the first month that data showed an increase in myocarditis. The agency also stopped using Spikevax Moderna vaccine Spikevax for children born before 1991.

According to the agency, Thursday’s pause was extended beyond Dec. 1, and anyone who received the Moderna vaccine will receive the Comirnaty vaccination from Pfizer/Biontech.

Comirnaty was approved by the European Medicines Agency in May. Spikevax, which is for older children (12 and over), received approval in July.

Also, the health agency stated that it is time to stop wide-scale testing. They will also remove recommendations for testing individuals who have been fully vaccinated even if symptoms are present.

“We have to test all those most likely to be infected by COVID-19. Britta Bjorkholm from the Health Agency stated that the vaccine is effective in protecting against not only severe diseases but also infection and spreading infection.

Around 85% have received one shot of the vaccine, while 80% of those 16 years and older have had at least two.

On November 1, the new guidelines for testing will be in effect. Patients and healthcare workers should continue to get tested. Those who were in direct contact with positive results should also be tested.

Last week there were 139 651 positive tests.

Sweden has a relatively low rate of deaths, hospitalisations, and cases compared to other European countries. It chose not to implement wide-ranging lockdowns, and instead relied on voluntary recommendations during the pandemic.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.